1. Psychometric properties of QI-Disability in CDKL5 Deficiency Disorder: Establishing readiness for clinical trials.
- Author
-
Saldaris JM, Jacoby P, Leonard H, Benke TA, Demarest S, Marsh ED, and Downs J
- Subjects
- Protein Serine-Threonine Kinases genetics, Psychometrics, Surveys and Questionnaires, Child, Reproducibility of Results, Humans, Adult, Epileptic Syndromes, Quality of Life psychology, Spasms, Infantile genetics
- Abstract
CDKL5 Deficiency Disorder (CDD) is a rare genetic disorder with symptoms of epilepsy, developmental impairments, and other comorbidities. Currently, there are no outcome measures for CDD with comprehensive evidence of validation. This study aimed to evaluate the psychometric properties of the Quality of Life Inventory-Disability (QI-Disability) in CDD. Quality of Life Inventory-Disability was administered to 152 parent caregivers registered with the International CDKL5 Disorder Database (ICDD). Confirmatory factor analysis was conducted and the goodness of fit of the factor structure was assessed. Fixed-effects linear regression models examined the responsiveness of QI-Disability to reported changes in child health. A subset of parent caregivers (n = 56) completed QI-Disability, as well as additional health-related questions, on two occasions separated by four weeks to evaluate test-retest reliability. Test-retest reliability was assessed using intra-class correlations (ICCs) calculated from QI-Disability scores. Based upon adjustments for changes in child health, ICCs were recalculated to estimate responsiveness to change. Confirmatory factor analysis, internal consistency, and divergent validity were mostly satisfactory, except divergent validity was not satisfactory for the Social Interactions and Independence domains. The Physical Health, Social Interactions, Leisure, and Total scores responded to changes in the child's Physical health, and the Negative Emotions and Leisure domains responded to changes in the child's behavior. Unadjusted and adjusted ICC values were above 0.8 for the Positive Emotions, Negative Emotions, Social Interactions, Leisure, Independence domains and Total score, and above 0.6 for the Physical Health domain. Findings suggest that QI-Disability is suitable to assess the quality of life of children and adults with CDD and could be of value for upcoming clinical trials., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Helen Leonard: Consultancy for Marinus, Newron, Anavex, GW Pharmaceuticals, Orion and AveXis; Clinical Trials with Newron and Anavex; All remuneration has been made to her department. Tim A. Benke: Consultancy for AveXis, Ovid, GW Pharmaceuticals, International Rett Syndrome Foundation, Takeda, Neurogene, Ultragenyx, Zogenix, GrinTherapeutics, Alcyone, and Marinus; Clinical Trials with Acadia, Ovid, GW Pharmaceuticals, Marinus, and RSRT; All remuneration has been made to his department. Scott Demarest: Consultancy for Biomarin, Neurogene, Marinus, Tysha, Ultragenyx, and Ovid Therapeutics. He has funding from the NIH, project 8P, and Mila's Miracle Foundation. He also serves on the advisory board for the non-profit foundations SLC6A1 Connect, Project 8P, Ring14 USA, and FamilieSCN2A. Eric Marsh: Consultancy for Stoke therapeutics, Cipla pharmaceuticals. Clinical trials with Acadia, GW pharma, Marinus, RSRT, Biopharm, Stoke therapeutics, and Zogenix Pharmaceuticals. Jenny Downs: Consultancy for Marinus, Newron, Ultragenyx, AveXis, Orion, and Taysha; Clinical Trials with Newron and Anavex; All remuneration has been made to her department. Peter Jacoby and Jacinta Saldaris report no disclosures or conflicts of interest., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF